Cipla Q4 disappoints; sales up 2.4%, net down 8%

Generic drug maker Cipla's fourth quarter sales grew marginally by 2.4 percent to Rs 1910 crore from Rs 1865 crore, a year ago. The company's operating profit margins improved by 270 basis points from 18 percent to 20.7 percent.
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead master your money Realasset
moneycontrol.com

Home » News » Earnings » Results

May 29, 2013, 07.11 PM | Source: Moneycontrol.com

Cipla Q4 disappoints; sales up 2.4%, net down 8%

Generic drug maker Cipla's fourth quarter sales grew marginally by 2.4 percent to Rs 1910 crore from Rs 1865 crore, a year ago. The company's operating profit margins improved by 270 basis points from 18 percent to 20.7 percent.

Like this story, share it with millions of investors on M3

Cipla Q4 disappoints; sales up 2.4%, net down 8%

Generic drug maker Cipla's fourth quarter sales grew marginally by 2.4 percent to Rs 1910 crore from Rs 1865 crore, a year ago. The company's operating profit margins improved by 270 basis points from 18 percent to 20.7 percent.

Post Your Comments

Share Cancel

Moneycontrol Bureau

Generic drug maker Cipla 's fourth quarter sales grew marginally by 2.4 percent to Rs 1910 crore from Rs 1865 crore, a year ago. The company's operating profit margins improved by 270 basis points from 18 percent to 20.7 percent.

Its net profit declined by 8.2 percent from Rs 292 crore to Rs 268 crore.

Analysts on an average had expected the company to post profit of Rs 331 crore on revenues of Rs 2093 crore.

Cipla's board has recommended a dividend of Rs 2 per equity share for the year 2012-2013.

Net profit for the year ended March 31, 2013 was higher at Rs 1,507.11 crore compared to Rs 1,123.96 crore, a year ago.

Total income for the fiscal year 2013 rose to Rs 8,202.42 crore from Rs 6,977.50 crore for the same period year ago.

Subhanu Saxena, CEO, Cipla said in an exclusive interview to CNBC-TV18, "The Indian brand generics market has witnessed slowdown but we will still invest in next phase of growth over the next 2 years."

Going forward the company's focus will be to make a robust portfolio outside India. "We are looking to re-establish our presence in US and Europe. Among emerging markets, the focus would be on China, Japan, Turkey and Brazil," he added.

The stock closed at Rs 401.55, up Rs 5 or 1.26 percent on Tuesday.

Ads by Google

Buy, Hold, Sell ? Hear it first on M3
Cipla Q4 disappoints; sales up 2.4%, net down 8%

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login